These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 22119201)
21. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698 [TBL] [Abstract][Full Text] [Related]
22. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199 [TBL] [Abstract][Full Text] [Related]
23. Association of breast cancer outcome with status of p53 and MDM2 SNP309. Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855 [TBL] [Abstract][Full Text] [Related]
24. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539 [TBL] [Abstract][Full Text] [Related]
25. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308 [TBL] [Abstract][Full Text] [Related]
26. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Nan H; Qureshi AA; Hunter DJ; Han J Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047 [TBL] [Abstract][Full Text] [Related]
27. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk. Gansmo LB; Romundstad P; Birkeland E; Hveem K; Vatten L; Knappskog S; Lønning PE Cancer Med; 2015 Dec; 4(12):1901-7. PubMed ID: 26471763 [TBL] [Abstract][Full Text] [Related]
28. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402 [TBL] [Abstract][Full Text] [Related]
29. A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients. Pan X; Li Y; Feng J; Wang X; Hao B; Shi R; Zhang G BMC Cancer; 2013 Mar; 13():126. PubMed ID: 23506213 [TBL] [Abstract][Full Text] [Related]
30. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis. Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195 [TBL] [Abstract][Full Text] [Related]
31. The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome. Renaux-Petel M; Sesboüé R; Baert-Desurmont S; Vasseur S; Fourneaux S; Bessenay E; Frébourg T; Bougeard G Fam Cancer; 2014 Mar; 13(1):127-30. PubMed ID: 23884452 [TBL] [Abstract][Full Text] [Related]
32. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873 [TBL] [Abstract][Full Text] [Related]
33. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750 [TBL] [Abstract][Full Text] [Related]
34. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569 [TBL] [Abstract][Full Text] [Related]
35. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Phang BH; Linn YC; Li H; Sabapathy K Eur J Cancer; 2008 Mar; 44(5):760-6. PubMed ID: 18313915 [TBL] [Abstract][Full Text] [Related]
36. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis. Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386 [TBL] [Abstract][Full Text] [Related]
37. Association of the Wang P; Wang M; Li S; Ma L; Xi S; He J Dis Markers; 2016; 2016():4585484. PubMed ID: 27890964 [TBL] [Abstract][Full Text] [Related]
38. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352 [TBL] [Abstract][Full Text] [Related]
39. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891 [TBL] [Abstract][Full Text] [Related]
40. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Petz LN; Nardulli AM Mol Endocrinol; 2000 Jul; 14(7):972-85. PubMed ID: 10894148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]